Davis Polk advised the underwriters in the initial public offering of RemeGen Co., Ltd. on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule 144A…
Davis Polk advised the joint lead managers and joint bookrunners in connection with an issuance of $500 million Regulation S offering by Yancoal International Resources Development Co.,…
Davis Polk advised the underwriters in connection with a $500 million Regulation S only offering by China SCE Group Holdings Limited of its 7.000% senior notes due 2025.
China SCE Group…
Davis Polk advised the underwriters in the initial public offering of JW (Cayman) Therapeutics Co. Ltd on the Hong Kong Stock Exchange and an international offering and listing in reliance…
Davis Polk advised the initial purchasers in connection with the Rule 144A/Regulation S offering by Meituan of $750 million 2.125% senior notes due 2025 and $1.25 billion 3.050% senior…
Davis Polk advised the underwriters in connection with a Regulation S offering by Hubei Science & Technology Investment Group (Hong Kong) Company Limited, a wholly owned subsidiary of…
Davis Polk advised the underwriters on an SEC-registered offering by Baidu, Inc. of its $650 million 1.720% notes due 2026 and $300 million 2.375% notes due 2030.
Baidu, Inc. is a leading…
Davis Polk advised Boqii Holding Limited on its SEC-registered initial public offering of 7,000,000 American depositary shares. Each ADS represents 0.75 Class A ordinary share of Boqii…
Davis Polk advised Kingsoft Cloud Holdings Limited and certain selling shareholders on its approximately $509 million SEC-registered follow-on public offering of 16,421,576 American…
Davis Polk advised Zai Lab Limited in connection with its secondary listing and initial public offering on the Hong Kong Stock Exchange. Zai Lab is the first company listed under both…